Literature DB >> 15925559

Targeted anticytokine therapy and the failing heart.

Douglas L Mann1.   

Abstract

Recent studies have identified the importance of proinflammatory mediators in the development and progression of chronic heart failure (CHF). The growing appreciation of the pathophysiologic consequences of sustained expression of proinflammatory mediators in preclinical and clinical CHF models culminated in a series of multicenter clinical trials that used targeted approaches to neutralize tumor necrosis factor in patients with moderate-to-advanced CHF. However, these targeted approaches have resulted in worsening CHF, thereby raising a number of important questions about what role, if any, proinflammatory cytokines play in the pathogenesis of CHF. This review summarizes what has been learned from the negative clinical trials, as well as the potential direction of future research in this area.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15925559     DOI: 10.1016/j.amjcard.2005.03.007

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  25 in total

1.  β2 adrenergic activation induces the expression of IL-18 binding protein, a potent inhibitor of isoproterenol induced cardiomyocyte hypertrophy in vitro and myocardial hypertrophy in vivo.

Authors:  David R Murray; Srinivas Mummidi; Anthony J Valente; Tadashi Yoshida; Naveen K Somanna; Patrice Delafontaine; Charles A Dinarello; Bysani Chandrasekar
Journal:  J Mol Cell Cardiol       Date:  2011-10-08       Impact factor: 5.000

Review 2.  Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload.

Authors:  Gabriele G Schiattarella; Joseph A Hill
Journal:  Circulation       Date:  2015-04-21       Impact factor: 29.690

3.  Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2).

Authors:  Benjamin W Van Tassell; Leo F Buckley; Salvatore Carbone; Cory R Trankle; Justin M Canada; Dave L Dixon; Nayef Abouzaki; Claudia Oddi-Erdle; Giuseppe Biondi-Zoccai; Ross Arena; Antonio Abbate
Journal:  Clin Cardiol       Date:  2017-05-05       Impact factor: 2.882

4.  The virtue of just enough stress: a molecular model.

Authors:  Nanette H Bishopric
Journal:  Trans Am Clin Climatol Assoc       Date:  2012

5.  Lycopene dietary intervention: a pilot study in patients with heart failure.

Authors:  Martha J Biddle; Terry A Lennie; Gregory V Bricker; Rachel E Kopec; Steven J Schwartz; Debra K Moser
Journal:  J Cardiovasc Nurs       Date:  2015 May-Jun       Impact factor: 2.083

6.  C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study.

Authors:  Eric S Williams; Sanjiv J Shah; Sadia Ali; Bee Ya Na; Nelson B Schiller; Mary A Whooley
Journal:  Eur J Heart Fail       Date:  2007-12-21       Impact factor: 15.534

7.  Mechanisms of Post-Infarct Left Ventricular Remodeling.

Authors:  Brent A French; Christopher M Kramer
Journal:  Drug Discov Today Dis Mech       Date:  2007

Review 8.  The TNF-α/sphingosine-1-phosphate signaling axis drives myogenic responsiveness in heart failure.

Authors:  Jeffrey T Kroetsch; Steffen-Sebastian Bolz
Journal:  J Vasc Res       Date:  2013-04-16       Impact factor: 1.934

9.  Blood-borne interleukin-1β acts on the subfornical organ to upregulate the sympathoexcitatory milieu of the hypothalamic paraventricular nucleus.

Authors:  Shun-Guang Wei; Yang Yu; Robert B Felder
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-11-22       Impact factor: 3.619

Review 10.  Pathological ventricular remodeling: mechanisms: part 1 of 2.

Authors:  Jana S Burchfield; Min Xie; Joseph A Hill
Journal:  Circulation       Date:  2013-07-23       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.